Clinical Trials Directory

A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Stanford is now accepting new patients for this trial. Please contact Karen Lau at 650-723-0658 for more information.



  • drug : Fulvestrant
  • drug : Trastuzumab
  • drug : Neratinib

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Karen Lau 650-723-0658

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: